A Specialized Laboratory and Rare Disease CRO

A Specialized Laboratory
and Rare Disease CRO
Reference Laboratory Services

That was fast!

Faster lab results lead to better patient outcomes. Our mission is "to save more lives with lab tests". We pursue that mission by developing and offering the fastest-in-the-nation lab services. Speed, quality and consistency are the 3 most important pillars of our operation.

Delivering results when they matter most.
"Thanks for getting the results to us so quickly. This patient’s case was quite complex. You guys are fantastic!"
Physician, Tower Health
West Reading, PA
"You saved my patient’s life; you made my day! (HIT testing) (August 2021)"
Staff Physician, SF Bay Area Medical Center
San Francisco, CA
"Machaon is fast! When you said you were the fastest reference lab in the US you weren't joking! I'm very impressed."
MD, Chair, Pediatric Neurosurgery
Chapel Hill, NC
"We contracted Machaon to set up and run a clinical trial. Mike was a real pleasure to work with, ensuring the trial approvals went through without issue, conducting the trial with a high degree of objectivity and integrity and providing an excellent and useful report. We were quite impressed with how much Machaon worked with us on making sure the best outcomes from the trial showed through."
PhD, managing director, nutraceutical firm
Hamilton, New Zealand
"Thank you for your responsiveness, support, and diligence through these past months."
Director of Operations

Featured Tests & Panels

Activated Protein C – Resistance

STAT: < 48 hours (M-F)

Ratio, Clot-based

Draw Tube: Blue Top

Used to evaluate patients with recurrent venous thrombosis. This is a second generation function assay. While most instances of APC resistance (APCR) are caused by the presence of Factor V Leiden (FVL), APCR may be abnormal with less common Factor V mutations, heparin, oral anticoagulants, lupus anticoagulants or other acquired causes. In cases where APCR is abnormal but FVL testing is normal, sequencing of the Factor V gene may be warranted to detect rare variants.

ADAMTS13 Activity

STAT: < 24 hours (7 days a week)

ELISA

Draw Tube: Blue Top

Machaon provides the fastest ADAMTS13 activity and inhibitor testing available in the US. Rapid diagnosis and administration of correct treatment is paramount for TTP and aHUS. This test is diagnostic for Thrombotic Thrombocytopenic Purpura (TTP) when ADAMTS13 Activity levels are below 10%. Consider other Thrombotic Microangiopathies (TMAs), such as atypical Hemolytic Uremic Syndrome (aHUS), for ADAMTS13 Activity levels above 10%.

ADAMTS13 Antibody

STAT: < 48 hours (M-F)

ELISA

Draw Tube: Blue Top

Detection of ADAMTS13 specific IgG antibodies may be an indication of a poorer prognosis for patients with abnormally low ADAMTS13 activity levels with a positive inhibitor.

ADAMTS13 Gene Sequencing

STAT: < 48 hours (M-F)

NGS

Draw Tube: Purple Top

Congenital Thrombotic Thrombocytopenic Purpura (cTTP) can be rapidly diagnosed with this test. Severe deficiency of ADAMTS13 activity, negative for an inhibitor, represent putative cases of Upshaw-Schulman syndrome; this autosomal recessive inherited form of TTP can be confirmed by gene sequencing.

ADAMTS13 Inhibitor

STAT: < 24 hours (7 days a week)

ELISA

Draw Tube: Blue Top

Machaon provides the fastest ADAMTS13 activity and inhibitor testing available in the US. Rapid diagnosis and administration of correct treatment is paramount for TTP and aHUS. This test is diagnostic for Thrombotic Thrombocytopenic Purpura (TTP) when ADAMTS13 Activity levels are below 10%. Consider other Thrombotic Microangiopathies (TMAs), such as atypical Hemolytic Uremic Syndrome (aHUS), for ADAMTS13 Activity levels above 10%.

ADAMTS13 Panel

STAT: < 24 hours (7 days a week)

ELISA

Draw Tube: Blue Top

This panel will confirm a diagnosis of TTP, differentiate between inherited and acquired forms of TTP, and provide an assessment of antibody level. ADAMTS13 Activity is diagnostic for Thrombotic Thrombocytopenic Purpura (TTP) when ADAMTS13 Activity levels are below 5-10%. Consider other Thrombotic Microangiopathies (TMAs), such as atypical Hemolytic Uremic Syndrome (aHUS), for ADAMTS13 levels above 10%. Early diagnosis and administration of correct treatment is paramount for TTP and aHUS. Testing for the presence of an inhibitor to ADAMTS13 helps differentiate between inherited and acquired Thrombotic Thrombocytopenic Purpura (TTP), while the ADAMTS13 Antibody assay provides a quantitative assessment of anti-ADAMTS13 antibody level. Rarely, cases of acquired TTP may occur due to antibodies that mediate increased clearance of ADAMTS13 but do not inhibit enzyme activity - these antibodies would be detected in the ADAMTS13 Antibody assay but not the ADAMTS13 Inhibitor assay.

aHUS Genetic Panel 3.0

STAT: < 48 hours (M-F)

NGS

Draw Tube: Purple Top

The clinical presentation of thrombotic microangiopathy (TMA) has been associated with multiple genetic disease including atypical hemolytic uremic syndrome (aHUS), thrombotic thrombocytopenic purpura (TTP), C3 glomerulopathy (C3G, comprising dense deposit disease and C3 glomerulonephritis), congenital B12 deficiency and others. These are difficult-to-diagnose, very sick patients with distinct treatment depending on the nature of the TMA. Accurate, rapid diagnosis is critical. Additionally, patients with the C5 p.Arg885 polymorphism may respond poorly to the current approved therapy, eculizumab. Note: this is the third time (3.0 name designation) we have updated the gene list to reflect the most current understanding of aHUS/TMA in the scientific literature.

Alpha-2 Antiplasmin Activity

STAT: < 1 week

Chromogenic

Draw Tube: Blue Top

Alpha-2-antiplasmin is the major physiologic inhibitor of plasmin. Reductions in alpha-2-antiplasmin have been associated with DIC, severe liver disease, malignancy, nephrotic syndrome and following thrombolytic therapy.

Alport Syndrome Genetic Panel

STAT: < 48 hours (M-F)

NGS

Draw Tube: Purple Top

Genetics can help confirm a diagnosis of Alport syndrome and may be especially helpful when the clinical phenotype is not clear-cut. Genetics can also inform family planning (for example, does an affected male have X-linked or autosomal Alport and is an affected female heterozygous or homozygous?).

Anti-CFH Antibody

STAT: < 48 hours (M-F)

ELISA

Draw Tube: Red Top

Factor H is a regulator of the alternative complement activation pathway. Acquired Factor H deficiency due to autoantibody production can lead to overactive complement. Continuous complement activation is associated with development of atypical Hemolytic Uremic Syndrome (aHUS) and Dense Deposit Disease (DDD).

Anticardiolipin Antibody (IgG, IgM, IgA)

STAT: < 48 hours (M-F)

ELISA

Draw Tube: Red Top

Anticardiolipin (ACL) antibodies are associated with antiphospholipid syndrome (APS). Persistently elevated levels of ACL antibodies are associated with an increased risk of vascular thrombosis and obstetrical complications.

Antiphosphatidylserine Antibody (IgG, Ig...

STAT: < 48 hours (M-F)

ELISA

Draw Tube: Red Top

The detection of anti-phosphatidylserine antibodies has been recommended for the serological diagnosis of antiphospholipid syndrome (APS). Antiphosphatidylserine antibodies have been associated with an increased risk for recurrent arterial and venous thrombotic events, thrombocytopenia and fetal loss.

Antiphosphatidylserine/Prothrombin Antib...

STAT: < 1 week

ELISA

Draw Tube: Blue Top

Draw Tube: Red Top

Antibodies to phosphatidylserine/prothrombin complex (aPS/PT) have been reported to be associated with antiphospholipid syndrome. This assay may be warranted in symptomatic patients, negative for APS criteria tests: LA, ACL and B2GPI.

Antiphospholipid Syndrome Criteria Panel

STAT: < 48 hours (M-F)

Clot-based, CIA

Draw Tube: Blue Top

Draw Tube: Red Top

This panel will detect laboratory abnormalities characteristic of Antiphospholipid Syndrome (APS), including the presence of a lupus anticoagulant, antibodies against the membrane phospholipid cardiolipin (IgG, IgM and IgA isotypes) and antibodies against B2GP1 (IgG, IgM and IgA isotypes). Catastrophic antiphospholipid syndrome (CAPS) is a rare, life-threatening form of APS characterized by the presence of a triple-positive APS lab work-up. Detecting a single, double, or triple positive result can significantly change patient management. Lupus anticoagulant and antiphospholipid antibodies increase the risk of arterial thrombosis, venous thrombosis, thrombocytopenia and recurrent miscarriage.

Antithrombin III Activity

STAT: < 24 hours (7 days a week)

Chromogenic

Draw Tube: Blue Top

Antithrombin III (ATIII) is a glycoprotein inhibitor of thrombin and factor Xa, whose activity is greatly potentiated by heparin. ATIII deficiencies are associated with a high risk of venous thromboembolic disease. Approximately 55 percent of patients with AT deficiency who have a family history of venous thromboembolism experience venous thrombotic episodes by the age of 50.

Antithrombin III Antigen

STAT: < 1 week

ELISA

Draw Tube: Blue Top

Antithrombin III (ATIII) is a glycoprotein inhibitor of thrombin and factor Xa, whose activity is greatly potentiated by heparin. ATIII deficiencies are associated with a high risk of venous thromboembolic disease. Approximately 55 percent of patients with AT deficiency who have a family history of venous thromboembolism experience venous thrombotic episodes by the age of 50.

Antithrombin III Gene Sequencing

STAT: < 48 hours (M-F)

NGS

Draw Tube: Purple Top

SERPINC1 is the gene encoding antithrombin III (AT3) protein. AT3 deficiency is a common cause of inherited thrombophilia and may be as prevalent as 1:2000. Sequencing may help confirm the diagnosis.

Apixaban level

STAT: < 1 week

Chromogenic

Draw Tube: Blue Top

Draw Tube: Red Top

Direct oral anticoagulants (DOACs) such as apixaban are monitored in select clinical situations such as kidney disease, urgent surgery, dosing concerns, compliance concerns and bleeding.

aPTT

STAT: < 24 hours (7 days a week)

Clot-based

Draw Tube: Blue Top

The activated Partial Thromboplastin Time (aPTT) is a general coagulation screening test for congenital and acquired deficiencies of the intrinsic and common coagulation pathway factors (XII, XI, IX, VIII, X, V, II, and I). This aPTT uses a reagent sensitive to factor deficiencies, lupus anticoagulants, and heparin. Machaon Diagnostics offers three different aPTT tests (aPTT, aPTT-LA, and aPTT-FS), each with different clinical utility based on differences in sensitivity to the presence of factor deficiencies and lupus anticoagulants.

aPTT Mixing Study

STAT: < 24 hours (7 days a week)

Clot-based

Draw Tube: Blue Top

Mixing studies are performed to determine whether prolongations in coagulation screening tests are due to coagulation factor deficiencies or the presence of an inhibitor. This can help direct further follow-up testing.

Machaon LIVE

MachaonLIVE.com is your window into real-time resulting, enabling immediate clinical action. You can receive your results by phone, fax, email and/or SMS text alerts.

  • 24/7 Access to Lab Results!
  • Order Tests
  • Secure Login
  • Access to the Fastest Turnaround Time in the Industry
  • Free Setup and Training

9 out of 10 Top Medical Centers Choose Machaon

Lab Testing and CRO Services United Under One Umbrella

Join the top medical centers (according to US News) that rely on Machaon Diagnostics to provide critical diagnostic services.

Why Machaon?

  • Often the Fastest TAT in the Industry
  • Expansive Specialized Tests
  • Lab Testing and CRO Services United Under One Umbrella
  • Customer First Approach

Who Else is Choosing Machaon?

  • 8 out of 10 largest global pharmaceutical companies
  • 8 out of 10 largest global CROs

80% of ALL medical decisions rely on lab test results.

Blood, Sweat & Smears

Blood, Sweat and Smears is a podcast hosted by Dr. Brad Lewis. This podcast focuses on bleeding, clotting, rare disease and complement-mediated disorders, as well as related news and events shaping current approaches in clinical management and laboratory medicine. Dr. Lewis shares his insights and knowledge built over his four decades as a benign hematologist. Subscribe to receive alerts on special guests, late-breaking news and the latest innovations coming to our area of medicine.

How to say “Machaon:”
chā
on

Who was Machaon?

Machaon is a character from Homer’s Iliad (800 B.C.) and a key figure in the Trojan War. Described as a warrior, surgeon and healer, Machaon was revered for saving the lives of Menelaus, King of Sparta, husband of beautiful Helen, and that of Philoctetes the famed Achaean leader. Under the direction of King Agamemnon, Machaon saved these and many other warriors during the fierce Greek and Trojan War.  Thus is the story of Machaon.

Partner with Us!

Our passion is to continually shine light on problems to uncover new techniques, solutions and approaches. This has made us a sought after specialized clinical laboratory and clinical trial partner by some of the world’s most prestigious institutions and firms. Hint: read our testimonials!